US4703002A - Method for preparing coating compositions containing an immunologically reactive species and elements containing same - Google Patents
Method for preparing coating compositions containing an immunologically reactive species and elements containing same Download PDFInfo
- Publication number
- US4703002A US4703002A US06/729,332 US72933285A US4703002A US 4703002 A US4703002 A US 4703002A US 72933285 A US72933285 A US 72933285A US 4703002 A US4703002 A US 4703002A
- Authority
- US
- United States
- Prior art keywords
- antibody
- milling
- coating composition
- creatine kinase
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title claims abstract description 55
- 239000008199 coating composition Substances 0.000 title claims abstract description 28
- 229920000642 polymer Polymers 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000003801 milling Methods 0.000 claims abstract description 21
- 230000007480 spreading Effects 0.000 claims description 35
- 238000003892 spreading Methods 0.000 claims description 35
- 239000011230 binding agent Substances 0.000 claims description 20
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 20
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 239000011236 particulate material Substances 0.000 claims description 13
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical group O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000012491 analyte Substances 0.000 claims description 11
- 229960003624 creatine Drugs 0.000 claims description 10
- 239000006046 creatine Substances 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000498 ball milling Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 239000004408 titanium dioxide Substances 0.000 claims description 6
- 102000004420 Creatine Kinase Human genes 0.000 claims description 5
- 108010042126 Creatine kinase Proteins 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 239000001023 inorganic pigment Substances 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 239000004576 sand Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 16
- 108010044467 Isoenzymes Proteins 0.000 description 20
- 238000003556 assay Methods 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- -1 poly(ethylene terephthalate) Polymers 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 4
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 4
- 229950006790 adenosine phosphate Drugs 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000984 immunochemical effect Effects 0.000 description 4
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000057621 Glycerol kinases Human genes 0.000 description 3
- 108700016170 Glycerol kinases Proteins 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- SFRDXVJWXWOTEW-UHFFFAOYSA-N 2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)CO SFRDXVJWXWOTEW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- MWVFCEVNXHTDNF-UHFFFAOYSA-N hexane-2,3-dione Chemical compound CCCC(=O)C(C)=O MWVFCEVNXHTDNF-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- KAICRBBQCRKMPO-UHFFFAOYSA-N phosphoric acid;pyridine-3,4-diamine Chemical compound OP(O)(O)=O.NC1=CC=NC=C1N KAICRBBQCRKMPO-UHFFFAOYSA-N 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- YGPKIBMJCWAHPF-UHFFFAOYSA-N 1,1-dichloroethane;1,2-xylene Chemical group CC(Cl)Cl.CC1=CC=CC=C1C YGPKIBMJCWAHPF-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 101710143182 Alpha-glycerophosphate oxidase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001082241 Lythrum hyssopifolia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- OIMACDRJUANHTJ-XPWFQUROSA-I P(1),P(5)-bis(5'-adenosyl) pentaphosphate(5-) Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 OIMACDRJUANHTJ-XPWFQUROSA-I 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 238000004313 potentiometry Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-VKHMYHEASA-N sn-glycerol 1-phosphate Chemical compound OC[C@H](O)COP(O)(O)=O AWUCVROLDVIAJX-VKHMYHEASA-N 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/808—Optical sensing apparatus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
Definitions
- the present invention relates to clinical chemistry.
- it relates to a method for preparing blush polymer coating compositions which contain an immunologically reactive species.
- It also relates to a method of making analytical elements containing the coating composition.
- this invention relates to elements particularly useful for assays of analytes in aqueous liquids, e.g. biological fluids.
- analytes aqueous fluids for chemical or biological substances
- the results of the analysis can be adversely affected by interfering materials. These materials either interfere with the reactivity of the analyte or act so similarly to it that the properties of analyte and interferent cannot be distinguished.
- interfering materials either interfere with the reactivity of the analyte or act so similarly to it that the properties of analyte and interferent cannot be distinguished.
- isoenzymes it is often necessary to minimize or eliminate the effect of the isoenzymes which are not of interest.
- Creatine kinase (abbreviated herein to CK, but also known as creatine phosphokinase, CPK, or ATP: creatine phosphotransferase E.C.2.7.3.2.) occurs in human body fluids and tissue in the form of three isoenzymes: CK-MM, for example in muscles, CK-BB, for example in the brain, and CK-MB, for example in the myocardium.
- the CK activity occurring in healthy human blood serum is normally due to the CK-MM isoenzyme because CK-BB does not generally pass into the blood stream.
- CK-MB is generally restricted to certain organs, for example the myocardium. However, when the myocardium is damaged, as in the case of a cardiac infarction, CK-MB is released into the blood stream and can be detected therein.
- a potential difficulty encountered in methods for determining CK-MB in biological fluids is interference from the other two isoenzymes. For practical purposes, the amount of CK-BB in the fluid is considered negligible in most determinations.
- a number of analytical elements having such spreading layers have been designed for various assays and used commercially, including an element useful for the determination of total CK.
- the spreading layer is coated and dried, and an aqueous suspension of the reagent(s) is applied to it and allowed to soak into the spreading layer.
- the aqueous medium carries the reagent(s) throughout the spreading layer.
- a dehydrated immunologically reactive species can be uniformly milled into a blush polymer spreading layer composition prior to coating and subsequently coated to provide a highly stable element under high humidity conditions. It was also surprising to us that the species remained active after milling in organic solvents because of the high shear and potentially deactivating environment of the process.
- the resulting element has improved room temperature (25° C.) keeping properties under the high humidity conditions (i.e. 50% relative humidity) generally encountered in manufacturing as well as during the ultimate use. In particular, the element exhibits at least about 75% retained sensitivity after being kept at 25° C. and 50% relative humidity for 6 days.
- a method for preparing a blush polymer coating composition containing an active immunologically reactive species comprises milling a dehydrated immunologically reactive species a particulate material and a polymeric binder material in an organic solvent for a time sufficient to uniformly disperse the species as particles less than about 5 ⁇ m in diameter in the binder material.
- This invention also provides a method for preparing an analytical element comprising a porous blush polymer layer containing an active immunologically reactive species. This method comprises applying the coating composition described above to a support.
- this invention provides an analytical element comprising a support having thereon a porous blush polymer spreading layer containing an active immunologically reactive species.
- This element exhibits at least about 75% retained sensitivity after being kept at 25° C. and 50% relative humidity for at least 6 days.
- FIG. 1 is a graphical illustration of transmission density (D T ) vs. time for the determination of CK-BB using elements prepared according to this invention compared to elements prepared by known techniques and demonstrating the improved stability obtained with this invention as discussed in Example 2 below.
- FIG. 2 is a graphical illustration of rate of change in transmission density (D T ) vs. CK-B activity for a number of compared elements as discussed in Example 3 below.
- FIG. 3 is a graphical illustration of rate of change in transmission density (D T ) vs. CK-B activity for a number of compared elements as discussed in Example 4 below.
- the present invention relates to the preparation of blush polymer coating compositions and the elements containing same which can be used to determine any of a number of analytes where it is desirable to have an active immunologically reactive species (e.g. antisera) in the element, preferably in a spreading layer.
- the resulting elements can be used to assay biological fluids of either humans or animals, but preferably of humans. Such fluids include, but are not limited to, whole blood, plasma, sera, lymph, bile, urine, spinal fluid, sputum, perspiration and the like as well as stool secretions.
- the elements can also be used to assay fluid preparations of human or animal tissue such as skeletal muscle, heart, kidney, lungs, brains, bone marrow, skin and the like.
- the elements of the present invention contain an active species which participates in an immunochemical reaction with a potentially interfering material in the fluid being assayed.
- immunochemically reactive species is meant to include any compound which will complex with a chemical or biological interferent and thereby limit its effect on the assay.
- such species include antibodies for a protein (e.g. and enzyme) found in antisera or small molecule (e.g. a therapeutic drug).
- the potential interferent is an antibody
- the species can be an anti-antibody, that is, a second antibody designed to complex with the first antibody.
- the immunologically reactive species is an antibody for an isoenzyme where that isoenzyme is a potential interferent for the determination of another isoenzyme.
- the element can be used to determine an isoenzyme of lactate dehydrogenase (LDH) with antisera containing antibodies for the undesired LDH isoenzymes.
- LDH-1 assay using immunochemical techniques is described in U.S. Pat. No. 4,224,406 (issued Sept. 23, 1980 to Gomez et al)
- the elements of this invention can be used in an immunochemical method for selectively determining CK-BB, CK-MM or CK-MB in a biological fluid which also possibly contains one or more of the isoenzymes.
- the CK-MM isoenzyme is a potentially significant interferent when CK-MB is to be measured. By removing the effect of this interferent, the detectable change produced in the assay can then be directly correlated to the amount of CK-MB in the fluid sample.
- the details of an assay, analytical element and the reagents needed for CK-MB determination are provided in copending and commonly owned U.S. Ser. No.
- the coating composition of this invention is prepared by milling a dehydrated immunologically reactive species, such as antisera containing antibodies, one or more particulate materials and one or more polymeric binders in one or more organic solvents.
- a dehydrated immunologically reactive species such as antisera containing antibodies, one or more particulate materials and one or more polymeric binders in one or more organic solvents.
- Antibodies useful n the practice of this invention which are specific to the interferent of concern, e.g. CK-MM, can be generated from antisera using known procedures.
- the antibodies can be isolated from the antisera before use, or unpurified antisera can be used.
- Antisera is generally obtained from suitably innoculated monkeys, pigs, horses, goats, rabbits, rats, mice, chickens, cattle, or other animals known to be useful for this purpose.
- a preferred source of antibodies are suitably innoculated goats.
- the antibodies are generally used in a substantially dried form (i.e. dehydrated form).
- the antisera can be dried using any suitable technique known to one skilled in the art. Generally, the antisera is lyophilized.
- Lyophilization is accomplished using known procedures, such as by conventional freeze drying processes. Further details of useful antibodies for CK-MM are provided, for example, in U.S. Pat. Nos. 4,237,044 (issued Dec. 2, 1980 to Wurzburg et al) and 4,260,678 (issued Apr. 7, 1981 to Lepp et al), the disclosure of which are incorporated herein by reference.
- Polymeric binders useful in preparing the coating composition of this invention include any polymers which can be made into a "blush" polymer layer. Such layers can be formed on a supporting material by dissolving a polymer in a mixture of two organic liquids, one of which is a lower boiling, good solvent for the polymer and the other being a higher boiling non-solvent or poor solvent for the polymer. Such a polymer solution is then coated on the supporting material, and dried under controlled conditions. The lower boiling solvent evaporates more readily and the coating can become enriched in the liquid which is a poor solvent or non-solvent. As evaporation proceeds under proper conditions, the polymer forms an isotropically porous layer. Many different polymers can be used, singly or in combination, for preparing isotropically porous blush polymer layers, examples being polycarbonates, polyamides, polyurethanes and cellulose esters. Cellulose acetate is a preferred polymer.
- the void volume of the resulting spreading layer is desirably at least about 25 percent.
- void volume can be controlled, for example, by selecting particulate materials of appropriate size, or by varying the solvents or drying conditions of the coating.
- the porosity be provided by including one or more particulate materials in the composition.
- Such materials are generally inorganic materials, such as inorganic pigments, which are chemically inert to sample components under assay. Pigments such as titanium dioxide, barium sulfate, zinc oxide, lead oxide, etc. are desirable, with titanium dioxide being most preferred.
- Other useful particulate materials include diatomaceous earth and microcrystalline colloidal materials derived from natural or synthetic polymers.
- Microcystalline cellulose which is commercially available as AvicelTM from FMC Corporation (Chicago, Ill.) is a useful colloidal material. Resinous or glass beads, are also useful. The particle size of the particles is not critical and can be chosen to give a desired porosity.
- the blush polymer coating composition materials are generally prepared in an organic solvent according to known procedures described, for example, in U.S. Pat. No. 3,992,158, noted above.
- Useful solvents vary depending upon the polymeric binders chosen.
- useful solvents include acetone, dichloroethane o-xylene and m-xylene, or a mixture of two or more of them.
- Other useful solvents for various binder materials include alcohols and the like. It was surprising that the immunologically reactive species remained active after being milled in the organic solvent environment.
- compositions of this invention can be included in the composition of this invention, including surfactants, buffers, resins, refractive pigments, etc.
- Some spreading layers contain reagents used in the assay.
- the composition preferably includes an activator for CK e.g. N-acetylcysteine.
- the particulate material is generally present in an amount which provides at least about 20, and preferably from about 40 to about 60, g/m 2 of dry coverage.
- the binder material is generally present in an amount to provide at least about 2, and preferably from about 5 to about 8, g/m 2 of dry coverage.
- the suitable amount of organic solvent used to prepare the compositions can be readily determined by a worker skilld in the art.
- the materials described above are milled together to form a uniform dispersion.
- milling techniques are useful, e.g. ball milling, pebble milling and sand milling.
- the amounts of materials, type of equipment and length of milling time are dependent on desired particle size, and can be determined by one skilled in the art.
- the time of milling is not critical as long as the antisera is uniformly dispersed within the polymeric binder material in acceptably small particle sizes, e.g. less than about 5 ⁇ m in diameter, and preferably less than about 3 ⁇ m in diameter.
- the other components of the composition are also uniformly dispersed in the polymeric binder with the milling.
- the immunologically reactive species e.g. antibodies, generally retains sufficient activity to reduce the activity of about 2,500 I.U./ ⁇ of CK-MM isoenzyme in human sera to less than about 5 I.U./ ⁇ .
- a support can be any suitable dimensionally stable, and preferably transparent (i.e. radiation transmissive) material which transmits electromagnetic radiation of a wavelength between about 200 and 900 nm.
- a support of choice for a particular element should compatible with the intended mode of detection (fluorescence or colorimetric spectroscopy).
- Useful supports can be made from paper, metal foils, polytyrene, polyesters [e.g. poly(ethylene terephthalate)], polycarbonates, cellulose esters (e.g. cellulose acetate), etc.
- the blush polymer spreading layer can be the sole layer in the element on the support. Alternatively, it can be one of two or more layers and be immediately adjacent to the support. Preferably it is the outermost layer of a multilayer element which has one or more intermediate layers between it and the support. Any of a number of intermediate layers can be incorporated in the element for various purposes as is known in the art, including particulate (e.g. beaded) or fibrous spreading layers which are not blush polymer layers, radiation-blocking layers, reagent layers, registration layers, subbing layers, filtering layers, barrier layers, etc. The composition of such layers is known to one skilled in the art as described in the Przybylowicz et al reference noted above as well as in U.S. Pat. Nos.
- an element is prepared having a support having thereon, in order and in fluid contact, a registration layer, a reagent layer and a spreading layer prepared from the blush polymer composition described above.
- This element is advantageously used to determine CK-MB and has a substrate for the enzyme, e.g. creatine phosphate, in the reagent layer and the appropriate reagents and indicator composition in one or more of the other layers.
- the details of such an element are provided in either of U.S. Ser. Nos. 729,331 or 729,333, noted above.
- Elements can be configured in a variety of forms, including elongated tapes of any desired width, sheets, slides or chips.
- the assay of this invention can be manual or automated.
- analyte e.g. CK isoenzyme
- determination is made by taking the element from a supply roll, chip packet or other source and physically contacting it with a sample (e.g. 1-100 ⁇ l) of the liquid to be tested.
- a sample e.g. 1-100 ⁇ l
- Such contact can be accomplished in any suitable manner, e.g. dipping or immersing the element into the sample or, preferably, by spotting the element by hand or machine with a drop of the sample with a suitable dispensing means.
- the element After sample application, the element is exposed to any conditioning, such as incubation, heating or the like, that may be desirable to quicken or otherwise facilitate obtaining any test result.
- any conditioning such as incubation, heating or the like, that may be desirable to quicken or otherwise facilitate obtaining any test result.
- the analyte e.g. CK isoenzyme
- the analyte added to the element in the test sample then catalyzes reaction of the reagents (e.g. ADP with the creatine phosphate substrate) at a rate based on the amount of analyte present in the sample.
- the rate of detectable change e.g. dye formation
- the reaction e.g. of creatine phosphate
- formation of the reaction product e.g. ATP
- suitable detection apparatus for reflection or transmission spectrophotometry, potentiometry or photometry is provided. Suitable detection apparatus and procedures are known in the art.
- EstaneTM 5715 polyurethane resin from B. F. Goodrich (Cleveland, Ohio), TritonTM X-200E and X-405 from Rohm and Haas (Philadelphia, Pa.), magnesium acetate from Allied Chemical Corp. (Morristown, N.J.), glycerol kinase from Worthington (Freehold, N.J.), adenosine-5'-monophosphate (AMP), adenosine-5'-diphosphate (ADP) and P 1 ,P 5 -di(adenosine-5')pentaphosphate (DAPP) from Sigma Chemical Co.
- I.U. represents the International Unit for enzyme activity defined as one I.U. being the amount of enzyme activity required to catalyze the conversion of 1 micromole of substrate per minute under standard pH and temperature conditions for the enzyme.
- percent sensitivity retained (% sens. ret.) is defined as:
- Rate 2 is the analyte activity determined using a test fluid containing a relatively high level of analyte
- Rate 1 is the analyte activity determined using a test fluid containing a relatively low level of analyte.
- High humidity is at least about 50% relative humidity (at 25° C.), and low humidity is at most 15% relative humidity (at -18° C.).
- the % sens. ret. is determined after the elements have been kept under defined conditions for a period of time, e.g. 6 or 7 days.
- a blush polymer coating composition was prepared in the following manner. This coating composition was useful in the preparation of an analytical element designed for the assay of CK-MB.
- Antisera containing goat anti-human CK-MM was obtained by immunizing goats with purified human CK-MM and withdrawing serum or plasma.
- the antisera was purified using known techniques in the art.
- the antisera was lyophilized to a dry powder by a conventional freeze drying process.
- the following dispersion was ball milled for at least 8 hours using conventional ball milling techniques: lyophilized antisera described above (200-500 m ⁇ ), ethylenebis(oxyethylenenitrilo)-tetraacetic acid (6-10 g), titanium dioxide (800 g), cellulose acetate (110 g) and TritonTM x-405 surfactant (26 g) in 1:1 acetone/m-xylene. After ball milling, 4-7 g of N-acetylcysteine CK activator was then mixed into the dispersion. The resulting coating composition contained the active antisera uniformly distributed within the polymeric binder material as particles having a diameter of less than about 5 ⁇ m.
- An analytical element having the format and components illustrated below was prepared using conventional coating techniques except for introducing antisera into the spreading layer.
- the spreading layer was formed by coating a ball milled coating composition prepared like that in Example 1 onto the underlying layers and drying it under controlled conditions to form a blush polymer layer.
- Control elements Similar analytical elements were prepared by wash coating the antisera into an already coated and dried blush polymer spreading layer having the same composition except for the antisera. No milling was used to prepare the Control spreading layer. These elements are labeled Control elements in this example.
- Both types of elements were tested for stability or keeping properties. Both elements were kept for 7 days under two different keeping conditions: 25° C. and 50% relative humidity, and -18° C. and 15% relative humidity. The elements were then used to determine the CK-BB isoenzyme activity in a test sample of fluid containing 247 I.U./ ⁇ CK-BB. The resulting dye formation in the elements was determined using a modified conventional spectrophotometer at 37° C. and 670 nm over seven minutes. FIG. 1 shows the results of these tests. Curves A-D of FIG. 1 are identified in Table I below.
- the data show that the element prepared according to the present invention has significantly improved stability and keeping properties over the Control element. This improvement is seen by comparing the small difference between curves A and B versus the larger difference between curves C and D.
- the difference between the two curves of each set of curves represents the loss in stability due to keeping under high humidity conditions (curves B and D).
- the greater the difference between the curves of each set the greater the instability of the element.
- the element prepared according to this invention whereby the antisera was ball milled into the spreading layer composition demonstrated significant stability improvement in high humidity environments.
- the Control element exhibited considerable stability loss.
- the element of the invention exhibited greater than about 75% sens. ret. whereas the Control element exhibited less than about 50% sens. ret.
- An analytical element was prepared similarly to that illustrated in Example 2 using conventional coating techniques.
- the spreading layer of the element was prepared by coating the ball milled coating composition of Example 1 onto the underlying layers and forming a blush polymer layer.
- This element was different from that of Example 2 in the placement of some reagents.
- the reagent layer contained ascorbic acid oxidase while the registration layer contained creatine phosphate, adenosine-5'-diphosphate, glycerol and glycerol kinase.
- Magnesium acetate was placed in both the reagent and registration layers.
- Controls Similar elements were prepared by wash coating the antisera into an already coated and dried blush polymer spreading layer having the same composition except for the antisera. No ball milling was used to prepare the Control spreading layer. These elements are labeled Controls in this example.
- Example 2 Each type of element was kept under the conditions described in Example 2 and tested for stability or keeping properties by spotting them with test fluids having known amounts of CK-BB isoenzyme. The rate of enzyme activity was measured between 6 and 7 minutes after incubation at 37° C. using a modified conventional spectrophotometer at 670 nm.
- FIG. 2 shows the results for each element. Table II below indicates the keeping conditions for the illustrated elements.
- CK-MB An analytical element useful for the determination of CK-MB was prepared according to the procedure and format described in Example 2. It was tested for stability and keeping properties according to the procedure described in Example 3 except that CK-MB was applied to the element instead of CK-BB.
- Controls Similar elements were prepared by wash coating the antisera into an already coated and dried blush polymer spreading layer having the same composition except for the antisera. No ball milling was used to prepare the Control spreading layer. These elements are labeled Controls in this example.
- Example 2 Each type of element was kept under the conditions described in Example 2 and tested for stability or keeping properties by spotting them with test fluids having known amounts of CK-MB isoenzyme.
- the rate of CK-MB activity was measured between 4 and 5 minutes after incubation at 37° C. using a modified conventional spectrophotometer at 670 nm and expressed as I.U. of CK-B per liter.
- FIG. 3 shows the results for each element. Table III below indicates the keeping conditions for the illustrated elements.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
[(Rate.sub.2 -Rate.sub.1) at high humidity÷(Rate.sub.2 -Rate.sub.1) at low humidity]×100
______________________________________ Spreading Goat anti-human CK-MM 5,000-300,000 Layer U/m.sup.2 Titanium dioxide 20-80 g/m.sup.2 Cellulose acetate 2-10 g/m.sup.2 N--acetyl-L-cysteine 0.2-0.6 g/m.sup.2 Ethylenebis(oxyethyl- 0.2-0.8 g/m.sup.2 enenitrilo)tetraace- tic acid Triton ™ X-405 0.5-3 g/m.sup.2 Subbing Poly(N--isopropylacrylamide) 0.2-0.6 g/m.sup.2 Layer Reagent Gelatin (hardened) 2-8 g/m.sup.2 Layer Magnesium acetate 0.2-2 g/m.sup.2 Triton ™ X-200E surfactant 0.005-0.5 g/m.sup.2 Glycerol kinase 2,000-10,000 I.U./m.sup.2 Adenosine-5'-diphosphate (ADP) 0.04-0.2 g/m.sup.2 Adenosine-5'-monophosphate (AMP) 0.2-2 g/m.sup.2 P.sub.1,P.sub.5 -di(adenosine-5')- 0.01-0.1 g/m.sup.2 pentaphosphate (DAPP) Glycerol 0.1-0.3 g/m.sup.2 Creatine phosphate 1-4 g/m.sup.2 2-[Bis(2-hydroxyethyl)imino]- 1-5 g/m.sup.2 2-(hydroxymethyl)-1,3-pro- panediol buffer Regis- Gelatin (hardened) 5-15 g/m.sup.2 tration 2-[Bis(2-hydroxyethyl)imino]- 1-5 g/m.sup.2 Layer 2-(hydroxymethyl)-1,3-pro- panediol buffer Alkanol XC ™ surfactant 0.1-0.5 g/m.sup.2 2-(3,5-Dimethoxy-4-hydroxy- 0.1-0.3 g/m.sup.2 phenyl)-4,5-bis(4-dimethyl- aminophenyl)imidazole Glycolic acid 0.1-0.5 g/m.sup.2 5,5-Dimethyl-1,3-cyclo- 0.01-5 g/m.sup.2 hexanedione Triton ™ X-200E surfactant 0.05-1 g/m.sup.2 2,4-Di- --pentylphenol 1-3 g/m.sup.2 Peroxidase 10,000-50,000 I.U./m.sup.2 Ascorbic acid oxidase 6,000-12,000 g/m.sup.2 L-α-Glycerophosphate 1,000-10,000 oxidase g/m.sup.2 Poly(ethylene terephthalate) Support ______________________________________
TABLE I ______________________________________ Curve - Element Keeping Conditions ______________________________________ A - Example 2 -18° C., 15% relative humidity B - Example 2 25° C., 50% relative humidity C - Control -18° C., 15% relative humidity D - Control 25° C., 50% relative humidity ______________________________________
TABLE II ______________________________________ Curve - Element Keeping Conditions ______________________________________ A - Example 3 -18° C., 15% relative humidity B - Example 3 25° C., 50% relative humidity C - Control -18° C., 15% relative humidity D - Control 25° C., 50% relative humidity ______________________________________
TABLE III ______________________________________ Curve - Element Keeping Conditions ______________________________________ A - Example 4 -18° C., 15% relative humidity B - Example 4 25° C., 50% relative humidity C - Control -18° C., 15% relative humidity D - Control 25° C., 50% relative humidity ______________________________________
Claims (20)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/729,332 US4703002A (en) | 1985-05-01 | 1985-05-01 | Method for preparing coating compositions containing an immunologically reactive species and elements containing same |
CA000484576A CA1251394A (en) | 1985-05-01 | 1985-06-20 | Method for preparing coating compositions containing an immunologically reactive species and elements containing same |
JP61098409A JPS61260164A (en) | 1985-05-01 | 1986-04-30 | Manufacture of coating composition containing antisera and element containing said composition |
DE8686303270T DE3674455D1 (en) | 1985-05-01 | 1986-04-30 | METHOD FOR PRODUCING LAYER COMPOSITIONS CONTAINING ANTISERA AND STRIPS CONTAINING THE SAME. |
EP86303270A EP0200539B1 (en) | 1985-05-01 | 1986-04-30 | Method of preparing coating compositions containing antisera and elements containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/729,332 US4703002A (en) | 1985-05-01 | 1985-05-01 | Method for preparing coating compositions containing an immunologically reactive species and elements containing same |
Publications (1)
Publication Number | Publication Date |
---|---|
US4703002A true US4703002A (en) | 1987-10-27 |
Family
ID=24930569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/729,332 Expired - Lifetime US4703002A (en) | 1985-05-01 | 1985-05-01 | Method for preparing coating compositions containing an immunologically reactive species and elements containing same |
Country Status (5)
Country | Link |
---|---|
US (1) | US4703002A (en) |
EP (1) | EP0200539B1 (en) |
JP (1) | JPS61260164A (en) |
CA (1) | CA1251394A (en) |
DE (1) | DE3674455D1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0562125A4 (en) * | 1991-10-11 | 1994-03-18 | Toray Industries | Antibody composition. |
US5496702A (en) * | 1994-09-01 | 1996-03-05 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay elements having stable leuco dye coatings |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8626081D0 (en) * | 1986-10-31 | 1986-12-03 | Unilever Plc | Printing processes |
JPH02253163A (en) * | 1989-03-27 | 1990-10-11 | Nitto Denko Corp | Method for forming physiologically active material to solid phase |
US6997343B2 (en) | 2001-11-14 | 2006-02-14 | Hypoguard Limited | Sensor dispensing device |
US7250095B2 (en) | 2002-07-11 | 2007-07-31 | Hypoguard Limited | Enzyme electrodes and method of manufacture |
US7264139B2 (en) | 2003-01-14 | 2007-09-04 | Hypoguard Limited | Sensor dispensing device |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992158A (en) * | 1973-08-16 | 1976-11-16 | Eastman Kodak Company | Integral analytical element |
US4052010A (en) * | 1974-03-01 | 1977-10-04 | Corning Glass Works | Suspendable porous glass particles |
US4067775A (en) * | 1975-11-03 | 1978-01-10 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process and composition for determining the activity of creatinekinase-MB |
US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
US4237044A (en) * | 1975-11-03 | 1980-12-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Antibodies against creatinekinase-M8 and process for the production thereof |
US4310513A (en) * | 1974-01-10 | 1982-01-12 | Institut Pasteur | Method of processing an active principle of a hydrophobic medicament and product thereof |
EP0116307A2 (en) * | 1983-01-18 | 1984-08-22 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Composition, analytical element and method for the quantification of creatine kinase |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4061466A (en) * | 1974-10-16 | 1977-12-06 | Ingvar Gosta Holger Sjoholm | Biologically active composition and the use thereof |
JPS5977356A (en) * | 1982-06-30 | 1984-05-02 | Fuji Photo Film Co Ltd | Multilayer analysis element for fluorescent assay and fluorescent assay using the same |
-
1985
- 1985-05-01 US US06/729,332 patent/US4703002A/en not_active Expired - Lifetime
- 1985-06-20 CA CA000484576A patent/CA1251394A/en not_active Expired
-
1986
- 1986-04-30 EP EP86303270A patent/EP0200539B1/en not_active Expired
- 1986-04-30 JP JP61098409A patent/JPS61260164A/en active Granted
- 1986-04-30 DE DE8686303270T patent/DE3674455D1/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3992158A (en) * | 1973-08-16 | 1976-11-16 | Eastman Kodak Company | Integral analytical element |
US4310513A (en) * | 1974-01-10 | 1982-01-12 | Institut Pasteur | Method of processing an active principle of a hydrophobic medicament and product thereof |
US4052010A (en) * | 1974-03-01 | 1977-10-04 | Corning Glass Works | Suspendable porous glass particles |
US4067775A (en) * | 1975-11-03 | 1978-01-10 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Process and composition for determining the activity of creatinekinase-MB |
US4237044A (en) * | 1975-11-03 | 1980-12-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Antibodies against creatinekinase-M8 and process for the production thereof |
US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
EP0116307A2 (en) * | 1983-01-18 | 1984-08-22 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Composition, analytical element and method for the quantification of creatine kinase |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0562125A4 (en) * | 1991-10-11 | 1994-03-18 | Toray Industries | Antibody composition. |
US5496702A (en) * | 1994-09-01 | 1996-03-05 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay elements having stable leuco dye coatings |
Also Published As
Publication number | Publication date |
---|---|
EP0200539A3 (en) | 1987-12-02 |
EP0200539B1 (en) | 1990-09-26 |
DE3674455D1 (en) | 1990-10-31 |
JPS61260164A (en) | 1986-11-18 |
CA1251394A (en) | 1989-03-21 |
JPH0565030B2 (en) | 1993-09-16 |
EP0200539A2 (en) | 1986-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4713327A (en) | Determination of total creatine kinase or an isoenzyme with a multilayer analytical element | |
JPH0549278B2 (en) | ||
EP0252750B1 (en) | Composition and analytical element having stabilized peroxidase | |
US4812399A (en) | Analytical element and method for the determination of creatinine or creatine | |
US4703002A (en) | Method for preparing coating compositions containing an immunologically reactive species and elements containing same | |
US4782016A (en) | Analytical element and method for determination of theophylline by enzyme inhibition | |
US4547460A (en) | Multizone analytical element and method for analyte determination | |
US4788140A (en) | Analytical element containing photosensitive compound and filter layer and method of use | |
US5294540A (en) | Ethanol analytical element | |
JPH0526865A (en) | Measuring method using dry process analysis element and dry process analysis element | |
US4746606A (en) | Bilirubin-specific enzyme and its analytical use | |
US6015683A (en) | Dry analytical element for acetaminophen assay | |
EP0158507B1 (en) | Reagent composition, dry element and method for determination of total bilirubin | |
US5185249A (en) | Dry analytical element for assaying salicylate | |
US4782017A (en) | Analytical element and method for determination of theophylline by enzyme inhibition | |
US5028528A (en) | Analytical element for theophylline determination using buffer in a subbing zone | |
EP0258035B1 (en) | Analytical element and method for theophylline determination having increased alkaline phosphatase isoenzyme | |
JPS63305254A (en) | Element and method for analysis of creatinine or creatine | |
JPH02245199A (en) | Measurement of one enzyme from mixture of isozyme and test carrier | |
US5416004A (en) | Multilayer analytical element containing primary amine buffer and method for the determination of ethanol | |
CA2017524A1 (en) | Dry creatinine analytical element and method for its use | |
JPH0394698A (en) | Integrated multi-layer analytic element containing ammonia determination reagent composition | |
JPS63119695A (en) | Integrated multi-layer analysis element for quantitative determination of neutral fat and production thereof | |
JPH0518957A (en) | Analytical element |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: EASTMAN KODAK COMPANY, ROCHESER, NEW YORK, A NJ CO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:FINDLAY, JOHN B.;WU, ANNIE L.;REEL/FRAME:004743/0828 Effective date: 19850430 Owner name: EASTMAN KODAK COMPANY, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FINDLAY, JOHN B.;WU, ANNIE L.;REEL/FRAME:004743/0828 Effective date: 19850430 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
AS | Assignment |
Owner name: CLINICAL DIAGNOSTIC SYSTEMS INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EASTMAN KODAK COMPANY;REEL/FRAME:007453/0348 Effective date: 19950118 |
|
FPAY | Fee payment |
Year of fee payment: 12 |